ACROMEGALY – ETIOLOGY, SYMPTOMS, TREATMENT. LITERATURE REVIEW
Abstract
Acromegaly is a rare endocrine disorder, typically resulting from a growth hormone (GH)-secreting pituitary adenoma. While these tumors are generally benign, they can sometimes exhibit local invasiveness or resistance to standard treatments. Clinically, the condition manifests through both distinctive physical changes and a range of systemic symptoms that may affect the cardiovascular, respiratory, metabolic, and neurological systems, and may also be associated with an increased risk of neoplastic diseases. Without timely treatment, these complications can significantly raise mortality risk, highlighting the importance of early detection. Initial screening usually includes measuring the levels of insulin-like growth factor 1 (IGF-1). Despite medical advancements, diagnosing acromegaly remains challenging, and delays in diagnosis are common, often resulting in advanced disease and severe complications. The preferred initial treatment is surgical resection of the tumor. For individuals who are ineligible for surgery or do not achieve remission postoperatively, medical therapy using somatostatin analogues is recommended. The primary therapeutic aims include normalization of IGF-1 and GH levels, reduction of tumor size, and management of associated complications.
References
Ershadinia, N., & Tritos, N. A. (2022). Diagnosis and Treatment of Acromegaly: An Update. Mayo Clinic proceedings, 97(2), 333–346. https://doi.org/10.1016/j.mayocp.2021.11.007
Melmed S. (2019). Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. The New England journal of medicine, 380(26), 2551–2562. https://doi.org/10.1056/NEJMra1817346
Hilczer M, Szalecki M. Regulacja wydzielania i działanie hormonu wzrostu. https://www.mp.pl/podrecznik/pediatria/chapter/B42.1.6.1.1.1
Lavrentaki, A., Paluzzi, A., Wass, J. A., & Karavitaki, N. (2017). Epidemiology of acromegaly: review of population studies. Pituitary, 20(1), 4–9. https://doi.org/10.1007/s11102-016-0754-x
Maione, L., & Chanson, P. (2019). National acromegaly registries. Best practice & research. Clinical endocrinology & metabolism, 33(2), 101264. https://doi.org/10.1016/j.beem.2019.02.001
Bolanowski M. Akromegalia - Nowe Spojrzenie Na Pacjenta :. Gdańsk: Via Medica; 2014.
Yamamoto, M., & Takahashi, Y. (2022). Genetic and Epigenetic Pathogenesis of Acromegaly. Cancers, 14(16), 3861. https://doi.org/10.3390/cancers14163861
Beckers, A., Aaltonen, L. A., Daly, A. F., & Karhu, A. (2013). Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocrine reviews, 34(2), 239–277. https://doi.org/10.1210/er.2012-1013
Hannah-Shmouni, F., Trivellin, G., & Stratakis, C. A. (2016). Genetics of gigantism and acromegaly. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 30-31, 37–41. https://doi.org/10.1016/j.ghir.2016.08.002
Cazabat, L., Bouligand, J., Salenave, S., Bernier, M., Gaillard, S., Parker, F., Young, J., Guiochon-Mantel, A., & Chanson, P. (2012). Germline AIP mutations in apparently sporadic pituitary adenomas: prevalence in a prospective single-center cohort of 443 patients. The Journal of clinical endocrinology and metabolism, 97(4), E663–E670. https://doi.org/10.1210/jc.2011-2291
Henriques, D. G., Lamback, E. B., Dezonne, R. S., Kasuki, L., & Gadelha, M. R. (2022). MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands. International journal of molecular sciences, 23(15), 8653. https://doi.org/10.3390/ijms23158653
Trivellin, G., Daly, A. F., Faucz, F. R., Yuan, B., Rostomyan, L., Larco, D. O., Schernthaner-Reiter, M. H., Szarek, E., Leal, L. F., Caberg, J. H., Castermans, E., Villa, C., Dimopoulos, A., Chittiboina, P., Xekouki, P., Shah, N., Metzger, D., Lysy, P. A., Ferrante, E., Strebkova, N., … Stratakis, C. A. (2014). Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. The New England journal of medicine, 371(25), 2363–2374. https://doi.org/10.1056/NEJMoa1408028
Slagboom, T. N. A., van Bunderen, C. C., De Vries, R., Bisschop, P. H., & Drent, M. L. (2023). Prevalence of clinical signs, symptoms and comorbidities at diagnosis of acromegaly: a systematic review in accordance with PRISMA guidelines. Pituitary, 26(4), 319–332. https://doi.org/10.1007/s11102-023-01322-7
Chanson, P., & Salenave, S. (2008). Acromegaly. Orphanet journal of rare diseases, 3, 17. https://doi.org/10.1186/1750-1172-3-17
Wang, Y., Guo, X., Liu, J., & Xing, B. (2023). Skin manifestations and submacroscopical features of acromegaly: A case-control study using dermoscopy and high-frequency ultrasound. Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 29(4), e13319. https://doi.org/10.1111/srt.13319
Colao, A., Ferone, D., Marzullo, P., & Lombardi, G. (2004). Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine reviews, 25(1), 102–152. https://doi.org/10.1210/er.2002-0022
Giustina, A., Casanueva, F. F., Cavagnini, F., Chanson, P., Clemmons, D., Frohman, L. A., Gaillard, R., Ho, K., Jaquet, P., Kleinberg, D. L., Lamberts, S. W., Lombardi, G., Sheppard, M., Strasburger, C. J., Vance, M. L., Wass, J. A., Melmed, S., & Pituitary Society and the European Neuroendocrine Association (2003). Diagnosis and treatment of acromegaly complications. Journal of endocrinological investigation, 26(12), 1242–1247. https://doi.org/10.1007/BF03349164
Giustina A. (2023). Acromegaly and Bone: An Update. Endocrinology and metabolism (Seoul, Korea), 38(6), 655–666. https://doi.org/10.3803/EnM.2023.601
Lombardi, G., Galdiero, M., Auriemma, R. S., Pivonello, R., & Colao, A. (2006). Acromegaly and the cardiovascular system. Neuroendocrinology, 83(3-4), 211–217. https://doi.org/10.1159/000095530
Kamenický, P., Maione, L., & Chanson, P. (2021). Cardiovascular complications of acromegaly. Annales d'endocrinologie, 82(3-4), 206–209. https://doi.org/10.1016/j.ando.2020.03.010
Sharma, M. D., Nguyen, A. V., Brown, S., & Robbins, R. J. (2017). Cardiovascular Disease in Acromegaly. Methodist DeBakey cardiovascular journal, 13(2), 64–67. https://doi.org/10.14797/mdcj-13-2-64
Yousseif, A., Karra, E., & Baldeweg, S. E. (2012). Acromegaly. British journal of hospital medicine (London, England : 2005), 73(8), C119–C123. https://doi.org/10.12968/hmed.2012.73.sup8.c119
Pivonello, R., Auriemma, R. S., Grasso, L. F., Pivonello, C., Simeoli, C., Patalano, R., Galdiero, M., & Colao, A. (2017). Complications of acromegaly: cardiovascular, respiratory and metabolic comorbidities. Pituitary, 20(1), 46–62. https://doi.org/10.1007/s11102-017-0797-7
Dineen R, Stewart PM, Sherlock M. Acromegaly. QJM. 2017;110(7):411-420. doi:10.1093/qjmed/hcw004
Mercado, M., & Ramírez-Rentería, C. (2018). Metabolic Complications of Acromegaly. Frontiers of hormone research, 49, 20–28. https://doi.org/10.1159/000486001
Zarool-Hassan, R., Conaglen, H. M., Conaglen, J. V., & Elston, M. S. (2016). Symptoms and signs of acromegaly: an ongoing need to raise awareness among healthcare practitioners. Journal of primary health care, 8(2), 157–163. https://doi.org/10.1071/HC15033
Matthesen, A. T., Rosendal, C., Christensen, E. H., Beckmann, H., Klit, F. Ø., Nikontovic, A., Bizik, G., Vestergaard, P., & Dal, J. (2025). Psychiatric morbidity in acromegaly: a cohort study and meta-analysis of the literature. Pituitary, 28(2), 42. https://doi.org/10.1007/s11102-025-01509-0
Schilbach, K., Strasburger, C. J., & Bidlingmaier, M. (2017). Biochemical investigations in diagnosis and follow up of acromegaly. Pituitary, 20(1), 33–45. https://doi.org/10.1007/s11102-017-0792-z
Bolanowski, M., Ruchała, M., Zgliczyński, W., Kos-Kudła, B., Hubalewska-Dydejczyk, A., & Lewiński, A. (2019). Diagnostics and treatment of acromegaly - updated recommendations of the Polish Society of Endocrinology. Endokrynologia Polska, 70(1), 2–18. https://doi.org/10.5603/EP.a2018.0093
Caron, P., Brue, T., Raverot, G., Tabarin, A., Cailleux, A., Delemer, B., Renoult, P. P., Houchard, A., Elaraki, F., & Chanson, P. (2019). Signs and symptoms of acromegaly at diagnosis: the physician's and the patient's perspectives in the ACRO-POLIS study. Endocrine, 63(1), 120–129. https://doi.org/10.1007/s12020-018-1764-4
Schilbach, K., Gar, C., Lechner, A., Nicolay, S. S., Schwerdt, L., Haenelt, M., Dal, J., Jørgensen, J. L., Störmann, S., Schopohl, J., & Bidlingmaier, M. (2019). Determinants of the growth hormone nadir during oral glucose tolerance test in adults. European journal of endocrinology, 181(1), 55–67. https://doi.org/10.1530/EJE-19-0139
Katznelson, L., Laws, E. R., Jr, Melmed, S., Molitch, M. E., Murad, M. H., Utz, A., Wass, J. A., & Endocrine Society (2014). Acromegaly: an endocrine society clinical practice guideline. The Journal of clinical endocrinology and metabolism, 99(11), 3933–3951. https://doi.org/10.1210/jc.2014-2700
Potorac, I., Petrossians, P., Daly, A. F., Alexopoulou, O., Borot, S., Sahnoun-Fathallah, M., Castinetti, F., Devuyst, F., Jaffrain-Rea, M. L., Briet, C., Luca, F., Lapoirie, M., Zoicas, F., Simoneau, I., Diallo, A. M., Muhammad, A., Kelestimur, F., Nazzari, E., Centeno, R. G., Webb, S. M., … Beckers, A. (2016). T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-related cancer, 23(11), 871–881. https://doi.org/10.1530/ERC-16-0356
Clemmons, D. R., & Bidlingmaier, M. (2023). Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly. Frontiers in endocrinology, 14, 1266339. https://doi.org/10.3389/fendo.2023.1266339
Zamanipoor Najafabadi, A. H., van der Meulen, M., Priego Zurita, A. L., Faisal Ahmed, S., van Furth, W. R., Charmandari, E., Hiort, O., Pereira, A. M., Dattani, M., Vitali, D., de Graaf, J. P., Biermasz, N. R., & MTG6 Pituitary of Endo-ERN (2022). Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study. Endocrine connections, 12(1), e220349. https://doi.org/10.1530/EC-22-0349
Pennlund, A., Esposito, D., Bontell, T. O., Skoglund, T., Hallén, T., Carén, H., Johannsson, G., & Olsson, D. S. (2025). Long-term clinical outcome of 103 patients with acromegaly after pituitary surgery. Pituitary, 28(2), 33. https://doi.org/10.1007/s11102-025-01503-6
Guinto, G., Guinto-Nishimura, G. Y., Uribe-Pacheco, R., Sangrador-Deitos, M. V., Villanueva-Castro, E., García-Iturbide, R., Gallardo, D., Guinto, P., Vargas, A., & Aréchiga, N. (2024). Surgical outcomes in patients with acromegaly: Microscopic vs. endoscopic transsphenoidal surgery. Best practice & research. Clinical endocrinology & metabolism, 38(4), 101879. https://doi.org/10.1016/j.beem.2024.101879
Störmann, S., Schopohl, J., Bullmann, C., Terkamp, C., Christ-Crain, M., Finke, R., Flitsch, J., Kreitschmann-Andermahr, I., Luger, A., Stalla, G., Houchard, A., Helbig, D., & Petersenn, S. (2021). Multicenter, Observational Study of Lanreotide Autogel for the Treatment of Patients with Acromegaly in Routine Clinical Practice in Germany, Austria and Switzerland. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 129(3), 224–233. https://doi.org/10.1055/a-1247-4713
Ferone, D., Freda, P., Katznelson, L., Gatto, F., Kadioğlu, P., Maffei, P., Seufert, J., Silverstein, J. M., Spencer-Segal, J. L., Isaeva, E., Dreval, A., Harrie, M., Svedberg, A., & Tiberg, F. (2025). Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1. The Journal of clinical endocrinology and metabolism, 110(6), 1729–1739. https://doi.org/10.1210/clinem/dgae707
Bolanowski, M., Hubalewska-Dydejczyk, A., Kos-Kudła, B., Ruchała, M., Witek, P., Zgliczyński, W., Houchard, A., & Bartmańska, M. (2021). Quality of life in patients with acromegaly receiving lanreotide autogel: a real-world observational study. Endokrynologia Polska, 72(5), 512–519. https://doi.org/10.5603/EP.a2021.0075
Gezer, E., Demirhan, Y., Selek, A., Cantürk, Z., Çetinarslan, B., Sözen, M., Köksalan, D., & Karatoprak, A. P. (2022). Comparison between somatostatin analog injections. Revista da Associacao Medica Brasileira (1992), 68(4), 514–518. https://doi.org/10.1590/1806-9282.20211224
Biagetti, B., Araujo-Castro, M., Tebe, C., Marazuela, M., & Puig-Domingo, M. (2025). Real-world evidence of effectiveness and safety of pasireotide in the treatment of acromegaly: a systematic review and meta-analysis. Reviews in endocrine & metabolic disorders, 26(1), 97–111. https://doi.org/10.1007/s11154-024-09928-3
Olarescu, N. C., Jørgensen, A. P., Atai, S., Wiedmann, M. K. H., Dahlberg, D., Bollerslev, J., & Heck, A. (2025). Pasireotide as first line medical therapy for selected patients with acromegaly. Pituitary, 28(3), 48. https://doi.org/10.1007/s11102-025-01514-3
Pirchio, R., Auriemma, R. S., Montini, M. E., Vergura, A., Pivonello, R., & Colao, A. (2023). Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience. Journal of endocrinological investigation, 46(5), 1027–1038. https://doi.org/10.1007/s40618-022-01980-7
MacFarlane, J., & Korbonits, M. (2024). Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess. Best practice & research. Clinical endocrinology & metabolism, 38(4), 101910. https://doi.org/10.1016/j.beem.2024.101910
Slavinsky, P., Gonzalez Pernas, M., Miragaya, K., Antico, J., Margni, A., Condomí Alcorta, M., & Katz, D. A. (2022). Gamma knife radiosurgery in pituitary adenomas. A single-center experience. Radiocirugía gamma knife en adenomas hipofisarios: experiencia en un Centro. Medicina, 82(1), 111–116.
Marques-Pamies M, Gil J, Sampedro-Nuñez M, Valassi E, Biagetti B, Giménez-Palop O, Hernández M, Martínez S, Carrato C, Villar-Taibo R, Araujo-Castro M, Blanco C, Simón-Muela I, Simó-Servat A, Xifra G, Vázquez F, Pavón I, Rosado JA, García-Centeno R, Zavala R, Hanzu FA, Mora M, Aulinas A, Vilarrasa N, Librizzi S, Calatayud M, de Miguel P, Alvarez-Escola C, Picó A, Salinas I, Fajardo-Montañana C, Cámara R, Bernabéu I, Jordà M, Webb SM, Marazuela M, Puig-Domingo M. Personalized Medicine in Acromegaly: The ACROFAST Study. J Clin Endocrinol Metab. 2024 Dec 18;110(1):30-40. doi: 10.1210/clinem/dgae444. Erratum in: J Clin Endocrinol Metab. 2024 Dec 18;110(1):e205-e206. https://doi.org/10.1210/clinem/dgae444
Views:
74
Downloads:
24
Copyright (c) 2025 Michał Ochwat, Katarzyna Dąbek, Aleksandra Kajtel, Anna Skowronek, Martyna Piekarska-Magiera, Adam Sielicki, Maria Ochwat, Tomasz Skowronek, Michał Oborski, Zofia Sudoł
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
